Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
NCT07101094
This study is recruiting at 14 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to understand treatment preference and satisfaction among adults with schizophrenia in the United States who are prescribed xanomeline and trospium chloride (X/T) therapy
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Schizophrenia
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- September 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- ATP Clinical Research - Costa Mesa · Orange, CA
- Lumos Clinical Research Center · San Jose, CA
Illinois · 1
- Evanston Hospital · Evanston, IL
Maryland · 1
- The Johns Hopkins Hospital · Baltimore, MD
Massachusetts · 1
- Boston Medical Center · Boston, MA
Nebraska · 1
- Omaha Insomnia and Psychiatric Services · Omaha, NE
New Jersey · 1
- Hackensack Meridian Health - Carrier Clinic · Belle Mead, NJ
New York · 1
- Radial - Manhattan · New York, NY
North Carolina · 2
- New Dawn Psychiatric Services, PLLC · Kinston, NC
- New Dimension Group · Rose Hill, NC
Ohio · 1
- Westlake Brain Health · Westlake, OH
South Carolina · 1
- Continuum Health Providers · Fort Mill, SC
Texas · 2
- Haracec Clinical Research · El Paso, TX
- C-Trilogy Outreach · Longview, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.